Thus, the future algorithms defining the treatment of major depression or other stress-related mental disorders will incorporate tests that stratify patients groups and match individual patients with highly specific agents, for example that target HPA axis components such as the GR, CRH1 receptors or FKBP5. GR antagonists, especially mifepristone, have provided very promising results for the treatment of psychotic depression so far and therefore could gain more relevance (76). This evidence concerns the gene NR3C1 and major depressive disorder.